Ricerc@Sapienza

Aim. To demonstrate clinical effectiveness of micronized palmitoylethanolamide-transpolydatin
combination in reducing endometriotic chronic pelvic pain. Other endometriotic-
pains were also assessed.
Methods. Systematic reviews of PubMed, SCIELO, Scopus, and AJOL. Randomized
trials and observational studies reporting a visual analogue scale for pain or similar in
endometriotic patients were reviewed. A mean improvement of visual analogue scale (or
visual analogue scale-like) scores at enrollment and at a three-month follow-up was assessed
and interpreted clinically.
Results. Four studies of poor quality were available. In a heterogeneous sample of
endometriotic patients with pain, the administration of micronized palmitoylethanolamide/
trans-polydatin (400 mg/40 mg) twice a day for three months provided a clinically
relevant improvement of chronic pelvic pain and dysmenorrhea while improving
deep dyspareunia to a limited degree. No clinically relevant improvement was found for
dyschezia.
Conclusion. More studies are warranted for assessing the drugs-related efficacy.